Wednesday, August 20, 2025 8/20/2025

Prevention of Fractures in Patients with Parkinson's Disease

Award Number: R01AG059417
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2018
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Prevention of Fractures in Patients with Parkinson's Disease - Patients with Parkinson's disease (PD) have a very high risk of fracture: about 2 to 3-fold increased risk of all fractures and 4-fold increased risk of hip fracture that may be due in large part to their very high risk of multiple falls. Compared with other patients who suffer fractures, PD patients have more severe consequences of fractures: they have twice the risk of dying following hip and pelvic fractures and longer and incomplete functional recovery, with worsening of Parkinson's disease. Crucially, men and women age 65 or older have a fracture risk that is so high, that even those with normal bone density (BMD) for age would warrant a therapy that has been proven to reduce fracture risk in patients with PD. However, very few PD patients age 65 of older receive a treatment for osteoporosis. There are several major barriers to treatment of PD patients with drugs for osteoporosis. 1) There is a lack of evidence that treatments reduce fracture risk in patients with PD whose risk of fractures may be due to multiple and more severe falls. 2) Standard osteoporosis screening and treatment may also be a barrier. Medical visits to assess fracture risk, test BMD, prescribe treatment, generally an oral drug, and then follow-up to monitor compliance and response to treatment, are particularly burdensome for patients with PD. 3) Most patients with PD do not continue taking oral osteoporosis drugs even for 1 year. We propose a randomized trial that addresses all of these barriers. 1) We will test the anti-fracture efficacy of Zoledronic acid (ZA) a very potent bisphosphonate that inhibits bone loss and decreased fracture risk in women with osteoporosis and patients with hip fractures. 2) We will give ZA intravenously at home without clinic visits. 3) ZA inhibits bone loss for at least 2 years overcoming noncompliance with oral drugs. We will enroll 3,500 men and women PD age 65 years or older from large health systems, patient communities, and referrals from neurologists in the Parkinson's Study Group. A movement disorders specialist will confirm the diagnosis of PD by telemedicine. We will then provide calcium and vitamin D supplements. A research nurse will visit the patient at home, check for potential contraindications to ZA and then administer IV ZA or placebo. We will then follow patients for 2 years to ascertain and confirm fractures. A successful result may revolutionize the care of patients with PD. It may lead to guidelines promoting home-based ZA treatment of older PD patients. ZA, rather than oral drugs, would become the 1st line treatment for patients with PD. The trial would demonstrate that home-based treatment with ZA, without other assessments, could reach all older PD patients without the need for burdensome medical visits. Thus, a positive result may lead to treatment of many more PD patients and a substantial reduction in the occurrence of disabling fractures in patients with PD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	SUTTER BAY HOSPITALS	475 BRANNAN ST STE 130	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	5	2/14/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $3,135,800 )
2024	2024	SUTTER BAY HOSPITALS	475 BRANNAN ST STE 130	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	5	6/4/2024	NON-COMPETING CONTINUATION	$3,135,800
														Subtotal = $3,135,800

Issue Date FY: 2023 ( Subtotal = $3,192,387 )
2023	2023	SUTTER BAY HOSPITALS	475 BRANNAN ST STE 130	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	4	6/9/2023	NON-COMPETING CONTINUATION	$3,192,387
														Subtotal = $3,192,387

Issue Date FY: 2022 ( Subtotal = $6,941,547 )
2022	2022	SUTTER BAY HOSPITALS	475 BRANNAN ST STE 130	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	3	5/3/2022	NON-COMPETING CONTINUATION	$6,941,547
														Subtotal = $6,941,547

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	SUTTER BAY HOSPITALS	633 FOLSOM ST FL 5	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	2	4/28/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $10,488,462 )
2020	2020	SUTTER BAY HOSPITALS	633 FOLSOM ST FL 5	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	2	3/11/2020	NON-COMPETING CONTINUATION	$10,488,462
														Subtotal = $10,488,462

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2018	SUTTER BAY HOSPITALS	633 FOLSOM ST FL 5	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	003	1	9/13/2019	NEW	$0
2019	2018	SUTTER BAY HOSPITALS	633 FOLSOM ST FL 5	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	1	1/31/2019	NEW	$0
2019	2018	SUTTER BAY HOSPITALS	633 FOLSOM ST FL 5	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	002	1	6/13/2019	NEW	$0
2019	2018	SUTTER BAY HOSPITALS	633 FOLSOM ST FL 5	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	001	1	6/6/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $8,842,229 )
2018	2018	SUTTER BAY HOSPITALS	633 FOLSOM ST FL 5	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	1	9/19/2018	NEW	$8,842,229
														Subtotal = $8,842,229

Grand Total All Awards = $32,600,425

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Prevention of Fractures in Patients with Parkinson's Disease

Award Number: R01AG059417

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2018

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer